Haemostatix Ltd Report issue

For profit Phase 2
Founded: Nottingham United Kingdom (2003)
Status: Acquired by Ergomed (2016)

Organization Overview

First Clinical Trial
2014
NCT02204930
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

peprostat (2 trials)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhage (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2